UMIN-CTR Clinical Trial

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Recruitment status No longer recruiting
Unique ID issued by UMIN UMIN000038871
Receipt No. R000044299
Scientific Title Efficacy trial of 4 weeks ingestion of the development code MSHF001 food
Date of disclosure of the study information 2019/12/13
Last modified on 2020/02/21

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title Efficacy trial of 4 weeks ingestion of the development code MSHF001 food
Acronym Efficacy trial of 4 weeks ingestion of the development code MSHF001 food
Scientific Title Efficacy trial of 4 weeks ingestion of the development code MSHF001 food
Scientific Title:Acronym Efficacy trial of 4 weeks ingestion of the development code MSHF001 food
Region
Japan

Condition
Condition Healthy adults
Classification by specialty
Not applicable Adult
Classification by malignancy Others
Genomic information NO

Objectives
Narrative objectives1 Evaluation of MSHF001 (development code) food ingestion effects on general malaise in healthy females.
Basic objectives2 Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase

Assessment
Primary outcomes Evaluation of 4 weeks ingestion of the development code MSHF001 food effects of on general malaise and so on.
Key secondary outcomes

Base
Study type Interventional

Study design
Basic design Parallel
Randomization Randomized
Randomization unit Individual
Blinding Double blind -all involved are blinded
Control Placebo
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms 5
Purpose of intervention Prevention
Type of intervention
Food
Interventions/Control_1 In healthy females aged 40 to 59 years with subjective symptoms of hot flash, daily ingestion of two MSHF001(development code) food tablets twice a day, after breakfast meals and at bed time for 4 weeks.
Interventions/Control_2 In healthy females aged 40 to 59 years with subjective symptoms of hot flash, daily ingestion of two placebo food tablets twice a day, after breakfast meals and at bed time for 4 weeks.
Interventions/Control_3 In healthy females aged 40 to 59 years without subjective symptoms of hot flash, daily ingestion of two MSHF001 (development code) food Tablets twice a day, after breakfast meals and at bed time for 4 weeks.
Interventions/Control_4 In healthy females aged 40 to 59 years without subjective symptoms of hot flash, daily ingestion of two placebo food Tablets twice a day, after breakfast meals and at bed time for 4 weeks.
Interventions/Control_5 In healthy females aged 20 to 35 years, no intervention. Performing only one measurement.
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
20 years-old <=
Age-upper limit
59 years-old >=
Gender Female
Key inclusion criteria -Healthy females
1.Subjects at climacteric period who have the symptoms of hot flushes.
2.Subjects at climacteric period who have the symptoms of hot flushes.
3.Subjects between ages 20 and 35 who have stable menstrual cycle.
Key exclusion criteria -Subjects with systemic illness.
-Subjects who are diagnosed as menopausal disorders.
-Subjects who are under Hormone Replacement Therapy, HRT, and/or medication which would affect blood hormone levels.
-Subjects who are outpatients or were treated by doctor within a month.
-Subjects who regularly take medicine.
-Subjects who regularly take medicines that affect menopausal symptoms.
-Subjects who are pregnant or lactating, or planned to become pregnant in the near future.
-Subjects with smoking habit.
-Subjects with drinking habit in 5 or more days a week.
-Subjects who have possibilities for emerging allergy to foods, metals, and drugs.
-Subjects with illnesses or diseases on their face, especially such as atopic dermatitis, or psoriasis, or severe acne.
-Subjects who habitually having specific polyphenol-rich health food and drink.
-Subjects with high anxiety questionnaire values.
-Subjects with high Kupperman Kohnenki Shohgai Index.
-Subjects who easily have skin rashes.
-Subjects with potential conflict of interest.
Target sample size 100

Research contact person
Name of lead principal investigator
1st name Naoki
Middle name
Last name Yamamoto
Organization Kao Corporation
Division name Biological Science Research
Zip code 321-3497
Address 2606, Akabane, Ichikai-machi, haga-gun, Tochigi, 321-3497, JAPAN
TEL +81-285-68-7538
Email yamamoto.naoki@kao.com

Public contact
Name of contact person
1st name Mayumi
Middle name
Last name Ohtsuka
Organization Kao Corporation
Division name Biological Science Research
Zip code 321-3497
Address 2606, Akabane, Ichikai-machi, haga-gun, Tochigi, 321-3497, JAPAN
TEL +81-285-68-7538
Homepage URL
Email ohtsuka.mayumi@kao.com

Sponsor
Institute Kao Corporation
Institute
Department

Funding Source
Organization Kao Corporation
Organization
Division
Category of Funding Organization Profit organization
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization Human Research Ethics Committee, Kao Corporation
Address 2-1-3 Bunka, Sumida-ku, Tokyo 131-8501, JAPAN
Tel +81-3-5630-7263
Email morisaki.naoko@kao.com

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions 花王株式会社(栃木県)
株式会社 リサーチ・アンド・ディベロプメント(東京)

Other administrative information
Date of disclosure of the study information
2019 Year 12 Month 13 Day

Related information
URL releasing protocol
Publication of results Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled 100
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status No longer recruiting
Date of protocol fixation
2019 Year 12 Month 04 Day
Date of IRB
2019 Year 12 Month 04 Day
Anticipated trial start date
2019 Year 12 Month 13 Day
Last follow-up date
2020 Year 04 Month 28 Day
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other
Other related information

Management information
Registered date
2019 Year 12 Month 13 Day
Last modified on
2020 Year 02 Month 21 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000044299

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name


Contact us.